All In Biotech

Drug Trial Radar · NCT00401375

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

Last checked: Nov 19, 2026Latest source record: Sep 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 524 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

524

Actual

Start

Oct 31, 2006

Primary completion

Feb 29, 2008

Study completion Feb 29, 2008

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
First posted
Nov 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of MNTX in participants who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen.

Conditions

  • Post-Operative Ileus (POI)

Interventions

  • MethylnaltrexoneDrug

    Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.

  • PlaceboDrug

    Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Bowel MovementTime frame: Day 1 (From the time of end of surgery [that is; from the first dose of study drug administration]) up to Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Progenics Pharmaceuticals

    Tarrytown, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.